Evidence & regulatory context
- Mechanism
- Not recorded
- Target
- Not recorded
- Injury models
- Chemical/toxin · Ischaemia-reperfusion
- Reported indication
- Not recorded
- First approval
- Not recorded
- Development stage
- Not recorded
- ChEMBL record
- Not recorded
- ChEMBL max phase
- Not recorded
- Synonyms
- Not recorded
- Note
- Not recorded
Clinical trials 0
0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.
No linked human trial in this dataset.
Preclinical evidence 2
2 studies reported at therapy level; 2 evidence entries itemised.
RatChemical/toxinSprague-DawleyFemalen = 24 rats total across three groups10 mg/kg twice per dayFollowing paraquat administration
Model: Paraquat induced acute lung injury (15 mg/kg paraquat intraperitoneally)
Compared with paraquat alone, 3-aminobenzamide significantly lowered serum lactate dehydrogenase and neopterin, tissue oxidative stress parameters, TGF-beta1 and histological injury scores, and significantly increased total antioxidant capacity, suggesting PARP inhibition minimises paraquat induced…
Extraction: extract · Supplied extraction confidence: 0.8. Machine-extracted fields require source verification.
RatIschaemia-reperfusionCardiacWistarFemaleIntraperitoneal30 mg/kg
Model: Acute myocardial infarction (coronary ligation model) with sham-operated controls
3-aminobenzamide restored infarction-induced depression of peak longitudinal systolic velocity in the left ventricular anterior and lateral walls and of peak centripetal systolic velocity in the anterior septum, improved multiple two-dimensional echocardiographic parameters, and reduced infarct siz…
Extraction: extract · Subtype source: rule · Supplied extraction confidence: 0.68. Machine-extracted fields require source verification.
